IPCALAB — Ipca Laboratories Balance Sheet
0.000.00%
- IN₹358.15bn
- IN₹374.90bn
- IN₹77.05bn
- 98
- 11
- 88
- 77
Annual balance sheet for Ipca Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | C2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 4,182 | 7,688 | 13,701 | 21,801 | 8,454 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 10,783 | 10,312 | 11,531 | 11,962 | 19,271 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 28,557 | 34,370 | 44,572 | 51,893 | 55,389 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 19,933 | 21,465 | 25,026 | 26,946 | 46,632 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 52,598 | 60,684 | 76,235 | 86,264 | 111,013 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 13,264 | 11,605 | 14,659 | 18,058 | 23,556 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 16,324 | 13,667 | 21,587 | 27,844 | 47,691 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 36,275 | 47,017 | 54,648 | 58,420 | 63,322 |
Total Liabilities & Shareholders' Equity | 52,598 | 60,684 | 76,235 | 86,264 | 111,013 |
Total Common Shares Outstanding |